Thank you, Madam Chair, for giving me the opportunity to respond and to provide more information.
At Health Canada, we have two policies in this area on which we have given the committee our deadlines and achievements. I've updated you on the one, and I'd like to have a chance to give you the information on the other as well.
I spoke about the implementation of the listeria policy, and we've talked a bit about that here. But in addition, the independent investigator suggested in her report that we also come up with a mechanism for giving priority either to food additives or other interventions that might have public health implications. So rather than simply considering them in the same lineup or queue as other food additives for review, the investigator suggested we have a mechanism for putting them in a fast track for approval if they have these broader implications.
I think my colleague, when she was here, also spoke about this timeframe. It's in fact the case that we've put in place this fast-track mechanism now. So we are now in the position of pulling things out and putting them in that fast-track process when they have these broader public health implications. In fact, we have used that process to approve some of the interventions I mentioned.
In addition, I think my colleague spoke about the fact that we wanted to put out a guidance document to industry so that they would know how to qualify for this faster-track process, so there would be a clear set of guidance to industry about how to identify their intervention as something that might qualify for the fast track. That's the guidance document that we said we would have out. We are on track to do that within the next month, in accordance with the timeframe mentioned before.